BETHESDA, Md., April 22, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that ASCO (the American Society for Clinical Oncology) has announced in its Annual Meeting program that the Company will present its DCVax-Direct clinical trial and technology in a general poster session at this year's ASCO meeting, taking place in Chicago May 30 through June 3. The abstract is number TPS3133, and the poster is number 189(a).
ASCO is the largest and most important annual conference on cancer treatments, with some 30,000 oncologists and other medical personnel, analysts and others attending from all over the world. Last year, immune therapy emerged as the top new focus area. This year, the focus on immune therapies like DCVax is expected to be even greater.
ASCO's acceptance of the abstract about the Company's DCVax-Direct technology and its large Phase I/II trial provides an opportunity for leading oncologists, analysts, investors and media to learn more about the unique DCVax-Direct program, now in trials on a range of multiple inoperable cancers. The abstract will be presented in a general poster session.
The Company will also have a large exhibit booth in the ASCO exhibit hall, where further information will be provided about the Company's DCVax technology. Its DCVax-L and DCVax-Direct clinical trial programs provide a series of customized vaccine injections which educate a patient's immune system to attack that individual's specific cancer without any toxic side effects. In clinical trials to date on a variety of solid tumor cancers, the results have been encouraging.DCVax-Direct specifically is a personalized immune therapy for inoperable solid tumors, using dendritic cells (the master cells of the immune system) to mobilize the immune system to attack the patient's cancer. DCVax-Direct is administered by direct injection into the patient's tumors. It can be injected into any number of tumors, enabling patients with locally advanced disease or with metastases to be treated. DCVax-Direct can also be injected into tumors in virtually any location in the body (with ultra-sound guidance for interior locations).